June 23, 2017 09:07 AM EDT
R&D
Pharma

PhI­II-fo­cused Cara sees shares spike on its new ‘break­through’ sta­tus at the FDA

John Carroll

Editor & Founder

Cara Ther­a­peu­tics $CARA has been through it all with their lead­ing, late-stage pro­gram for IV CR845, a pain ther­a­py that in­spired an IPO, a swoon­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Neu­mora's ma­jor de­pres­sion drug flunks first of three Phase 3 tri­als

Roche cir­cles back to Chi­na biotech with $80M deal for lung can­cer ADC

Pfiz­er ends work on Sang­amo's he­mo­phil­ia gene ther­a­py, crush­ing biotech's hopes

Flag­ship biotech Va­lo Health ends 2024 with mid-stage fail

No­var­tis ends Phase 1 ra­dio­phar­ma tri­al; Solve Ther­a­peu­tics pur­sues $75M round

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

A service from the Financial Times